/Investor DB

REDMILE — 2018 Investments

2 investments dated 2018 · listed companies and verified rows first · show all

OncoResponseoncoresponseinc.comSep 2018 · $40M

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

BoardSteven Gillis(Director)in

Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaARCH Venture Partners+5 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Attenua

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.